Skip to main content
OB

Onreal Biotechnology

The startup develops non-invasive diagnostic technology for cancer detection using advanced imaging and biomarker analysis methods. This platform provides rapid and accurate results without invasive procedures, enhancing patient comfort and improving diagnostic reliability.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Traditional cancer diagnostic methods often involve invasive procedures, causing patient discomfort and potential complications. The reliance on biopsies and surgical interventions can lead to delays in diagnosis and treatment initiation.

Solution

This startup is developing a non-invasive diagnostic platform for cancer detection, leveraging advanced imaging techniques and biomarker analysis. The technology aims to provide rapid and accurate results, eliminating the need for invasive procedures. By analyzing specific biomarkers and utilizing sophisticated imaging, the platform seeks to enhance diagnostic reliability and improve patient comfort. This approach allows for earlier detection and monitoring of cancerous conditions, potentially leading to more effective treatment strategies and improved patient outcomes. The platform's non-invasive nature also reduces the risks associated with traditional diagnostic methods.

Target Audience

The primary target audience includes oncologists, radiologists, and hospitals seeking to improve cancer detection rates and reduce patient discomfort associated with traditional diagnostic methods.

Features

  • Advanced imaging modalities for detailed visualization of potential tumor sites.
  • Proprietary biomarker analysis techniques for early cancer detection.
  • Non-invasive sample collection methods.
  • Rapid results turnaround time.
  • High diagnostic accuracy and sensitivity.
This profile is AI-generated and may contain inaccuracies.